These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 21916908

  • 21. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 23. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 24. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET, Steel SA, Aye M, Doherty SM.
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [Abstract] [Full Text] [Related]

  • 25. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG, Shaw H.
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [Abstract] [Full Text] [Related]

  • 26. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA, Schousboe JT, Cline RR, Weiss TW.
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [Abstract] [Full Text] [Related]

  • 27. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 28. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Jan; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 29. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 30. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [Abstract] [Full Text] [Related]

  • 31. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [Abstract] [Full Text] [Related]

  • 32. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 33. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 34. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 35. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [Abstract] [Full Text] [Related]

  • 36. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 37. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Jul; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
    Wade SW, Satram-Hoang S, Nadkar A, Macarios D, Tosteson AN.
    Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.